tetano
Editor, Senior Moderator
Clin Infect Dis
. 2025 Aug 20:ciaf355.
doi: 10.1093/cid/ciaf355. Online ahead of print. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab
Nandita Nadig[SUP] 1 [/SUP], Adarsh Bhimraj[SUP] 2 [/SUP], Kelly Cawcutt[SUP] 3 [/SUP], Kathleen Chiotos[SUP] 4 [/SUP], Amy L Dzierba[SUP] 5 [/SUP], Arthur Y Kim[SUP] 6 7 [/SUP], Greg S Martin[SUP] 8 [/SUP], Jeffrey C Pearson[SUP] 9 [/SUP], Amy Hirsch Shumaker[SUP] 10 11 [/SUP], Lindsey R Baden[SUP] 6 12 [/SUP], Roger Bedimo[SUP] 13 [/SUP], Vincent Chi-Chung Cheng[SUP] 14 [/SUP], Kara W Chew[SUP] 15 [/SUP], Eric S Daar[SUP] 16 [/SUP], David V Glidden[SUP] 17 [/SUP], Erica J Hardy[SUP] 18 [/SUP], Steven Johnson[SUP] 19 [/SUP], Jonathan Z Li[SUP] 6 12 [/SUP], Christine MacBrayne[SUP] 20 [/SUP], Mari M Nakamura[SUP] 21 22 [/SUP], Laura Riley[SUP] 23 24 [/SUP], Robert W Shafer[SUP] 25 [/SUP], Shmuel Shoham[SUP] 26 [/SUP], Pablo Tebas[SUP] 27 [/SUP], Phyllis C Tien[SUP] 28 [/SUP], Jennifer Loveless[SUP] 29 [/SUP], Yngve Falck-Ytter[SUP] 10 11 [/SUP], Rebecca L Morgan[SUP] 10 30 [/SUP], Rajesh T Gandhi[SUP] 6 7 [/SUP]
Affiliations
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of infliximab in hospitalized adults with severe or critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.
Keywords: COVID-19; SARS-CoV-2; guideline; infliximab; monoclonal antibody.
. 2025 Aug 20:ciaf355.
doi: 10.1093/cid/ciaf355. Online ahead of print. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab
Nandita Nadig[SUP] 1 [/SUP], Adarsh Bhimraj[SUP] 2 [/SUP], Kelly Cawcutt[SUP] 3 [/SUP], Kathleen Chiotos[SUP] 4 [/SUP], Amy L Dzierba[SUP] 5 [/SUP], Arthur Y Kim[SUP] 6 7 [/SUP], Greg S Martin[SUP] 8 [/SUP], Jeffrey C Pearson[SUP] 9 [/SUP], Amy Hirsch Shumaker[SUP] 10 11 [/SUP], Lindsey R Baden[SUP] 6 12 [/SUP], Roger Bedimo[SUP] 13 [/SUP], Vincent Chi-Chung Cheng[SUP] 14 [/SUP], Kara W Chew[SUP] 15 [/SUP], Eric S Daar[SUP] 16 [/SUP], David V Glidden[SUP] 17 [/SUP], Erica J Hardy[SUP] 18 [/SUP], Steven Johnson[SUP] 19 [/SUP], Jonathan Z Li[SUP] 6 12 [/SUP], Christine MacBrayne[SUP] 20 [/SUP], Mari M Nakamura[SUP] 21 22 [/SUP], Laura Riley[SUP] 23 24 [/SUP], Robert W Shafer[SUP] 25 [/SUP], Shmuel Shoham[SUP] 26 [/SUP], Pablo Tebas[SUP] 27 [/SUP], Phyllis C Tien[SUP] 28 [/SUP], Jennifer Loveless[SUP] 29 [/SUP], Yngve Falck-Ytter[SUP] 10 11 [/SUP], Rebecca L Morgan[SUP] 10 30 [/SUP], Rajesh T Gandhi[SUP] 6 7 [/SUP]
Affiliations
- PMID: 40831386
- DOI: 10.1093/cid/ciaf355
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of infliximab in hospitalized adults with severe or critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.
Keywords: COVID-19; SARS-CoV-2; guideline; infliximab; monoclonal antibody.